{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:02:06Z","timestamp":1789516926899,"version":"build-2803163510"},"reference-count":68,"publisher":"Georg Thieme Verlag KG","issue":"CP","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background Thromboembolic complications are common in patients with pancreatic cancer, with up to 20% of patients developing venous thromboembolism. While hypercoagulation in pancreatic cancer has been widely studied, fibrinolysis is less well characterized. Plasmin generation (PG) is a novel approach to assess fibrinolytic activity and may provide new insights into thrombotic risk in this population. This study aimed to compare the PG profile of patients with pancreatic cancer with that of healthy individuals.<\/jats:p>\n                  <jats:p>Methods This single-center cohort study included patients with advanced pancreatic cancer initiating chemotherapy at the Maastricht University Medical Center between 2022 and 2023. Plasma samples were obtained before chemotherapy (t\n                  0) and 8 weeks later (t\n                  8). PG and thrombin generation (TG) were measured; TG\/PG ratios were calculated to evaluate the balance between coagulation and fibrinolysis. Thromboembolic events were recorded for 6 months.<\/jats:p>\n                  <jats:p>Results In total, 18 patients with pancreatic cancer and 18 healthy subjects were included. At baseline, patients showed higher endogenous plasmin potential levels compared with controls, whereas PG remained elevated at t\n                  8 despite chemotherapy. PG lag time was prolonged in patients at t\n                  8. Patients showed lower TG\/PG ratios for endogenous thrombin\/plasmin potential. Five patients (28%) developed thromboembolic events. Although PG parameters were not associated with thromboembolic events, patients who developed thromboembolic events showed lower TG\/PG potential ratios.<\/jats:p>\n                  <jats:p>Conclusion Patients with pancreatic cancer exhibited a disbalance in their PG profile, with a delayed but increased capacity to generate plasmin. Future studies are required to assess whether PG associates with thromboembolic disease and survival.<\/jats:p>","DOI":"10.1055\/a-2925-6824","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:41:56Z","timestamp":1785368516000},"source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Plasmin Generation Kinetics Reveal a Hyperfibrinolytic Phenotype in Patients with Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1055","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5999-5685","authenticated-orcid":false,"given":"Dana","family":"Huskens","sequence":"first","affiliation":[{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Functional Coagulation"]},{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Platelet Pathophysiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"de Vos-Geelen","sequence":"first","affiliation":[{"name":"Maastricht University Medical Center, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Internal Medicine, Division of Medical Oncology"]},{"name":"GROW, Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Limburg, The Netherlands","place":["Maastricht"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5157-0191","authenticated-orcid":false,"given":"Ruth A.L.","family":"Willems","sequence":"additional","affiliation":[{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Functional Coagulation"]},{"name":"Maastricht University Medical Center, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Internal Medicine, Division of Medical Oncology and Vascular Medicine"]},{"name":"Thrombosis Expert Center Maastricht, Maastricht University Medical Center, Limburg, The Netherlands","place":["Maastricht"]},{"name":"CARIM, School for Cardiovascular Diseases, Maastricht University, Limburg, The Netherlands","place":["Maastricht"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"De Simone","sequence":"additional","affiliation":[{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Functional Coagulation"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Tufaha","sequence":"additional","affiliation":[{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Functional Coagulation"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"Konings","sequence":"additional","affiliation":[{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Functional Coagulation"]},{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Platelet Pathophysiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmen","family":"Middelveld","sequence":"additional","affiliation":[{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Functional Coagulation"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol","family":"Pepels-Aarts","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Center, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Internal Medicine, Division of Medical Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7796-4463","authenticated-orcid":false,"given":"Hugo Ten","family":"Cate","sequence":"additional","affiliation":[{"name":"Thrombosis Expert Center Maastricht, Maastricht University Medical Center, Limburg, The Netherlands","place":["Maastricht"]},{"name":"CARIM, School for Cardiovascular Diseases, Maastricht University, Limburg, The Netherlands","place":["Maastricht"]},{"name":"Maastricht University Medical Center, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Internal Medicine, Division of Vascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"De Laat","sequence":"additional","affiliation":[{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Functional Coagulation"]},{"name":"CARIM, School for Cardiovascular Diseases, Maastricht University, Limburg, The Netherlands","place":["Maastricht"]},{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Platelet Pathophysiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roest","sequence":"additional","affiliation":[{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Functional Coagulation"]},{"name":"Synapse Research Institute, Limburg, The Netherlands","place":["Maastricht"],"department":["Department of Platelet Pathophysiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.beha.2008.12.001","article-title":"Epidemiology of cancer-related venous thromboembolism","volume":"22","author":"T Wun","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases","volume":"49","author":"A J Walker","year":"2013","journal-title":"Eur J Cancer"},{"issue":"14","key":"ref3","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1053\/j.gastro.2019.12.009","article-title":"BACAP consortium. Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes","volume":"158","author":"C Frere","year":"2020","journal-title":"Gastroenterology"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3390\/cancers10110432","article-title":"Incidence, risk factors, and outcomes of arterial thromboembolism in patients with pancreatic cancer following palliative chemotherapy","volume":"10","author":"Y S Hung","year":"2018","journal-title":"Cancers"},{"issue":"08","key":"ref6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"B B Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"e0133","DOI":"10.1097\/MD.0000000000010133","article-title":"Higher stroke incidence in the patients with pancreatic cancer: a nation-based cohort study in Taiwan","volume":"97","author":"P C Chan","year":"2018","journal-title":"Medicine"},{"issue":"14","key":"ref8","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.3390\/cancers15143546","article-title":"Venous thromboembolism and primary thromboprophylaxis in perioperative pancreatic cancer care","volume":"15","author":"R AL Willems","year":"2023","journal-title":"Cancers"},{"issue":"16","key":"ref9","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"N S Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.6004\/jnccn.2024.0046","article-title":"Cancer-associated venous thromboembolic disease, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"M B Streiff","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"ESMO guidelines committee. Electronic address: clinicalguidelines@esmo.Org. Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"A Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"A A Khorana","year":"2008","journal-title":"Blood"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/bloodadvances.2021006484","article-title":"Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy","volume":"6","author":"T F Overvad","year":"2022","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","article-title":"The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer","volume":"150","author":"N van Es","year":"2017","journal-title":"Thromb Res"},{"issue":"10","key":"ref16","first-page":"1181","article-title":"Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"M B Streiff","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"International initiative on thrombosis and cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"D Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-019-0510-x","article-title":"The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues","volume":"121","author":"E Campello","year":"2019","journal-title":"Br J Cancer"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"101346","DOI":"10.1016\/j.beha.2022.101346","article-title":"Mechanisms of thrombosis in pancreatic ductal adenocarcinoma","volume":"35","author":"E Campello","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-0043-1777304","article-title":"Cellular components contributing to the development of venous thrombosis in patients with pancreatic cancer","volume":"50","author":"R AL Willems","year":"2024","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jtha.2023.12.037","article-title":"Altered whole blood thrombin generation and hyperresponsive platelets in patients with pancreatic cancer","volume":"22","author":"R AL Willems","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/bloodadvances.2020003149","article-title":"Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer","volume":"5","author":"Y Hisada","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/1097-0142(19920615)69:12<2884::AID-CNCR2820691204>3.0.CO;2-S","article-title":"Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma","volume":"69","author":"A Andr\u00e9n-Sandberg","year":"1992","journal-title":"Cancer"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/EJA.0b013e328334df31","article-title":"Thromboelastographic changes in liver and pancreatic cancer surgery: hypercoagulability, hypocoagulability or normocoagulability?","volume":"27","author":"L De Pietri","year":"2010","journal-title":"Eur J Anaesthesiol"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/MBC.0000000000000040","article-title":"Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer","volume":"25","author":"V G Nielsen","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"02","key":"ref26","first-page":"104","article-title":"Determinants of hypofibrinolysis in patients with digestive tract cancer","volume":"11","author":"K Gronostaj","year":"2016","journal-title":"Prz Gastroenterol"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/jth.15114","article-title":"Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery","volume":"19","author":"A Miszta","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"19","key":"ref28","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.2019004267","article-title":"A high-fat diet delays plasmin generation in a thrombomodulin-dependent manner in mice","volume":"135","author":"A Miszta","year":"2020","journal-title":"Blood"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/MBC.0000000000000559","article-title":"D-dimer predicts prognosis and non-resectability in patients with pancreatic cancer: a prospective cohort study","volume":"27","author":"M T Stender","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"106094","DOI":"10.1016\/j.rmed.2020.106094","article-title":"Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation","volume":"171","author":"L N van der Vorm","year":"2020","journal-title":"Respir Med"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/jth.13656","article-title":"Development of shiny app tools to simplify and standardize the analysis of hemostasis assay data: communication from the SSC of the ISTH","volume":"15","author":"C Longstaff","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1373\/jalm.2017.023630","article-title":"Interindividual variability and normal ranges of whole blood and plasma thrombin generation","volume":"2","author":"S Bloemen","year":"2017","journal-title":"J Appl Lab Med"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"H C Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.jtha.2025.02.034","article-title":"Patients with cirrhosis have a disbalance between coagulation and fibrinolysis resulting in a prothrombotic phenotype","volume":"23","author":"R AL Willems","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref35","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3324\/haematol.2011.054718","article-title":"High D-dimer levels are associated with poor prognosis in cancer patients","volume":"97","author":"C Ay","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/ATVBAHA.121.316463","article-title":"Hemostatic biomarkers and venous thromboembolism are associated with mortality and response to chemotherapy in patients with pancreatic cancer","volume":"41","author":"F Moik","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/01.coc.0000436088.69084.22","article-title":"Clinical and prognostic significance of coagulation assays in pancreatic cancer patients with absence of venous thromboembolism","volume":"38","author":"W Sun","year":"2015","journal-title":"Am J Clin Oncol"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12253-017-0206-6","article-title":"Much more than trousseau syndrome. The broad spectrum of the pancreatic paraneoplastic syndromes","volume":"24","author":"A Zalatnai","year":"2018","journal-title":"Pathol Oncol Res"},{"issue":"9165","key":"ref39","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(99)01046-6","article-title":"Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study","volume":"353","author":"M I Schmidt","year":"1999","journal-title":"Lancet"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2013-07-517060","article-title":"Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep\/wake cycle","volume":"123","author":"F AJL Scheer","year":"2014","journal-title":"Blood"},{"issue":"08","key":"ref41","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1538-7836.2005.01420.x","article-title":"PAI-1 and atherothrombosis","volume":"3","author":"D E Vaughan","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0049-3848(87)90202-7","article-title":"Kinetic analyses of the activation of Glu-plasminogen by urokinase in the presence of fibrin, fibrinogen or its degradation products","volume":"46","author":"Y Watahiki","year":"1987","journal-title":"Thromb Res"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1538-7836.2007.02824.x","article-title":"Coagulation factors and the protein C system as determinants of thrombin generation in a normal population","volume":"6","author":"A W Dielis","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref44","first-page":"553","article-title":"Thrombin generation, a function test of the haemostatic-thrombotic system","volume":"96","author":"H C Hemker","year":"2006","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref45","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood.V106.11.1957.1957","article-title":"Inhibition of thrombin cleavage of factor VIII by fibrinogen \u03b3\u2032 chain carboxyl terminus","volume":"106","author":"D H Farrell","year":"2005","journal-title":"Blood"},{"issue":"01","key":"ref46","first-page":"105","article-title":"Update on antithrombin I (fibrin)","volume":"98","author":"M W Mosesson","year":"2007","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref47","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s11239-025-03118-x","article-title":"Clot formation, structure, and fibrinolysis of plasma from pancreatic cancer patients","volume":"58","author":"R A Risman","year":"2025","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.124.321603","article-title":"Profibrinolytic factors and cancer progression, metastasis, and survival","volume":"45","author":"Y Hisada","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/ng1297-439","article-title":"Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation","volume":"17","author":"P Carmeliet","year":"1997","journal-title":"Nat Genet"},{"issue":"04","key":"ref50","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0092-8674(00)80429-8","article-title":"ECM and cell surface proteolysis: regulating cellular ecology","volume":"91","author":"Z Werb","year":"1997","journal-title":"Cell"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.addr.2015.11.010","article-title":"Cancer therapy targeting the fibrinolytic system","volume":"99","author":"B Heissig","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-4615-5391-5_9","article-title":"Proteases and protease inhibitors in tumor progression","volume":"425","author":"Y A DeClerck","year":"1997","journal-title":"Adv Exp Med Biol"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1165\/rcmb.2006-0006OC","article-title":"Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix","volume":"35","author":"H Matsuoka","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1159\/000051082","article-title":"Plasmin-mediated fibroblast growth factor-2 mobilisation supports smooth muscle cell proliferation in human saphenous vein","volume":"38","author":"S J George","year":"2001","journal-title":"J Vasc Res"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1210\/endo.140.12.7224","article-title":"Potential mechanisms for the plasmin-mediated release and activation of latent transforming growth factor-\u03b21 from the extracellular matrix of growth plate chondrocytes","volume":"140","author":"H A Pedrozo","year":"1999","journal-title":"Endocrinology"},{"issue":"22","key":"ref56","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.2003.05.165","article-title":"Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism","volume":"21","author":"N Goldenberg","year":"2003","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1053\/gast.2002.31885","article-title":"Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells","volume":"122","author":"V M D\u00edaz","year":"2002","journal-title":"Gastroenterology"},{"issue":"02","key":"ref58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1440-1746.2004.03531.x","article-title":"Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction","volume":"20","author":"A Nielsen","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"issue":"30","key":"ref59","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1038\/onc.2017.63","article-title":"Australian pancreatic cancer genome initiative. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer","volume":"36","author":"N LE Harris","year":"2017","journal-title":"Oncogene"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00268-006-0289-9","article-title":"High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma","volume":"31","author":"R Smith","year":"2007","journal-title":"World J Surg"},{"issue":"06","key":"ref61","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jjco\/hyi094","article-title":"Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer","volume":"35","author":"S J Shin","year":"2005","journal-title":"Jpn J Clin Oncol"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.onc.1201564","article-title":"The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro","volume":"16","author":"R Paciucci","year":"1998","journal-title":"Oncogene"},{"issue":"02","key":"ref63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pan.2022.12.012","article-title":"Plasma soluble urokinase-type plasminogen activator receptor (P-suPAR) in the diagnostics between malignant and non-malignant pancreatic lesions","volume":"23","author":"A Aronen","year":"2023","journal-title":"Pancreatology"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/1878-0261.13552","article-title":"Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression","volume":"18","author":"N N Chowdhury","year":"2024","journal-title":"Mol Oncol"},{"issue":"17","key":"ref65","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-05-0946","article-title":"Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice","volume":"65","author":"T W Bauer","year":"2005","journal-title":"Cancer Res"},{"issue":"06","key":"ref66","doi-asserted-by":"crossref","first-page":"e70073","DOI":"10.1002\/jev2.70073","article-title":"The procoagulant and fibrinolytic balance of extracellular vesicles predicts mortality in septic shock patients","volume":"14","author":"R Lacroix","year":"2025","journal-title":"J Extracell Vesicles"},{"issue":"04","key":"ref67","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/ATVBAHA.117.310262","article-title":"Distinct pathogenesis of pancreatic cancer microvesicle-associated venous thrombosis identifies new antithrombotic targets in vivo","volume":"38","author":"K Stark","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"ref68","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1111\/jth.12012","article-title":"Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method","volume":"10","author":"R Loeffen","year":"2012","journal-title":"J Thromb Haemost"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2925-6824.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:03:55Z","timestamp":1789513435000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2925-6824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":68,"journal-issue":{"issue":"CP","published-online":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026]]}},"alternative-id":["a29256824"],"URL":"https:\/\/doi.org\/10.1055\/a-2925-6824","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,29]]},"published":{"date-parts":[[2026,7,29]]}}}